Piper Jaffray Companies reiterated their buy rating on shares of Zoetis (NYSE:ZTS) in a report issued on Thursday. Piper Jaffray Companies currently has a $86.00 price target on the stock.
Other analysts have also recently issued research reports about the company. BidaskClub cut Zoetis from a strong-buy rating to a buy rating in a research report on Wednesday, September 20th. BMO Capital Markets lifted their target price on Zoetis from $65.00 to $70.00 and gave the stock a market perform rating in a research report on Friday, November 3rd. Zacks Investment Research cut Zoetis from a buy rating to a hold rating in a research report on Wednesday, November 1st. Stifel Nicolaus reiterated a buy rating and set a $65.00 target price on shares of Zoetis in a research report on Tuesday, October 24th. Finally, Cantor Fitzgerald reiterated a buy rating and set a $75.00 target price on shares of Zoetis in a research report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. Zoetis currently has a consensus rating of Buy and an average target price of $73.72.
Shares of Zoetis (NYSE:ZTS) opened at $76.62 on Thursday. Zoetis has a 52 week low of $52.00 and a 52 week high of $77.03. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $37,340.00, a price-to-earnings ratio of 40.33, a price-to-earnings-growth ratio of 1.83 and a beta of 1.06.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter in the previous year, the firm earned $0.52 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. equities research analysts predict that Zoetis will post 2.36 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be issued a dividend of $0.126 per share. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.66%. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is currently 26.32%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after buying an additional 230 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of Zoetis during the third quarter worth about $114,000. Harfst & Associates Inc. grew its holdings in shares of Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after buying an additional 260 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Zoetis by 251.9% during the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after buying an additional 1,360 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. grew its holdings in shares of Zoetis by 86.5% during the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after buying an additional 1,040 shares during the last quarter. 93.14% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/21/zoetis-zts-buy-rating-reiterated-at-piper-jaffray-companies.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.